NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions

N/ACompletedNCT01703000

Boston Scientific Corporation100 enrolled

Overview

NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)

To evaluate clinical and peri-procedural angiographic and intravascular ultrasound (IVUS) outcomes for the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) in the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥ 2.50 mm to ≤ 4.0 mm in diameter (by visual estimate)

Study Type

INTERVENTIONAL

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Atherosclerosis Coronary Artery Disease

Interventions

Percutaneous coronary intervention (NG PROMUS)DEVICE

Interventional coronary artery stenting with NG PROMUS study stent.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Clinical Inclusion Criteria: 1. Subject must be at least 18 years of age 2. Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed 3. Subject is eligible for percutaneous coronary intervention (PCI) 4. Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia 5. Subject is an acceptable candidate for coronary artery bypass grafting (CABG) 6. Subject is willing to comply with all protocol-required follow-up evaluation Angiographic Inclusion Criteria: 1. Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.50 mm and ≤4.0 mm 2. Target lesion(s) length must be ≤34 mm (by visual estimate) 3. Target lesion(s) must have visually estimated stenosis ≥50% and \<100% with thrombolysis in Myocardial Infarction (TIMI) flow \>1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress test or imaging stress test, or elevated biomarkers) prior to procedure 4. Coronary anatomy is likely to allow delivery of a study device to the target lesions(s) 5. The first lesion treated must be successfully pre-dilated/pretreated Note: Successful pre-dilatation/pretreatment refers to dilatation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C. Clinical Exclusion Criteria: 1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI) 2. Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina 3. Subject has received an organ transplant or is on a waiting list for an organ transplant 4. Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure 5. Planned PCI (including staged procedures) or CABG after the index procedure 6. Subject previously treated at any time with intravascular brachytherapy 7. Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin) 8. Subject has one of the following (as assessed prior to the index procedure):Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months; Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.);Planned procedure that may cause non-compliance with the protocol or confound data interpretation 9. Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome 10. Subject has a platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3 11. Subject has a white blood cell (WBC) count \< 3,000 cells/mm3 12. Subject has documented or suspected liver disease, including laboratory evidence of hepatitis 13. Subject is on dialysis or has baseline serum creatinine level \>2.0 mg/dL (177µmol/L) 14. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions 15. Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months 16. Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding 17. Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure 18. Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint 19. Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure 20. Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure) 21. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) Angiographic Exclusion Criteria: 1. Planned treatment of more than 3 lesions. 2. Planned treatment of lesions in more than 2 major epicardial vessels 3. Planned treatment of a single lesion with more than 1 stent 4. Subject has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate) 5. Target lesion(s) is located in the left main 6. Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate. 7. Target lesion(s) is located within a saphenous vein graft or an arterial graft 8. Target lesion(s) will be accessed via a saphenous vein graft or arterial graft 9. Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing 10. Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent) 11. Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent 12. Subject has unprotected left main coronary artery disease (\>50% diameter stenosis) 13. Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure 14. Thrombus, or possible thrombus, present in the target vessel (by visual estimate)

Locations (9)

Fremantle Hospital

Fremantle, Western Australia, Australia

Mercy Angiography Unit, Ltd. Mercy Hospital

Auckland, New Zealand

Auckland City Hospital

Auckland, New Zealand

North Shore Hospital

Auckland, New Zealand

Outcomes

Primary Outcomes

Technical Success Rate

Technical success is defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of \<30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day

Secondary Outcomes

Target Lesion Revascularization (TLR) Rate

Target lesion revascularization is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. A TLR will be considered as ischemia-driven if the target lesion diameter stenosis is \>/= 50% by QCA and there is presence of clinical or functional ischemia which cannot be explained by other coronary or graft lesions. Clinical or functional ischemia is any of the following: * The subject has a positive functional study corresponding to the area served by the target lesion. * The subject has ischemic ECG changes at rest in a distribution consistent with the target vessel. * The subject has ischemic symptoms referable to the target lesion. A TLR will be considered as ischemia-driven if the lesion diameter stenosis is \>/= 70% by QCA even in the absence of clinical or functional ischemia.

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Target Lesion Failure (TLF) Rate

Target lesion failure is any ischemia-driven revascularization of the target lesion, MI (Q-wave and non-Q-wave) related to the target vessel, or (cardiac) death. For the purposes of this protocol, if it cannot be determined with certainty whether the MI was related to the target vessel, it will be considered a TLF. The MI definition used for Target Lesion Failure was the PLATINUM MI definition.

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

NCT01703000 - NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions | Crick | Crick